PanCancer Progression Panel
Helping Your Research
Cancer progression involves multiple processes and mechanisms that are highly interconnected. The nCounter PanCancer Progression Panel lets you perform multiplex gene expression analysis with 770 genes from each step in the cancer progression process including: angiogenesis, extracellular matrix remodeling (ECM), epithelial-to-mesenchymal transition (EMT) and metastasis.
- Comprehensive gene expression analysis of cancer progression
- Quantify gene expression of metastatic growth and suppressor genes
- Rapidly and easily screen samples for biomarker discovery or drug mechanism of action to support your research
- Customizable with up to 55 additional user-defined genes with Panel Plus option
- 3D-enabled for multi-analyte analysis with Vantage 3D™ Assays
Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.
How It Works
Progression Panel Gene Coverage
The following is a pictorial description of the processes and key genes included in the PanCancer Progression Panel
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
360 Series Product Comparison
Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler
Breast cancer is a heterogenous disease with variability in tumor cells and in the surrounding tumor microenvironment (TME). Understanding the molecular diversity in breast cancer is critical for improving prediction of therapeutic response and prognostication.
Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma
Histiocytic sarcoma (HS) is a rare and aggressive tumor in humans with no universally agreed standard of care therapy. Spontaneous canine HS exhibits increased prevalence in specific breeds, shares key genetic and biologic similarities with the human disease, and occurs in an immunocompetent setting.
Spatially organized multicellular immune hubs in human colorectal cancer.
Immune responses to cancer are highly variable, with mismatch repair-deficient (MMRd) tumors exhibiting more anti-tumor immunity than mismatch repair-proficient (MMRp) tumors. To understand the rules governing these varied responses, we transcriptionally profiled 371,223 cells from colorectal tumors and adjacent normal tissues of 28 MMRp and 34 MMRd individuals.